Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) Other Non Operating Income (2016 - 2025)

Aptevo Therapeutics' Other Non Operating Income history spans 11 years, with the latest figure at $61000.0 for Q3 2025.

  • For Q3 2025, Other Non Operating Income fell 45.54% year-over-year to $61000.0; the TTM value through Sep 2025 reached $225000.0, down 61.86%, while the annual FY2024 figure was $472000.0, 18.34% down from the prior year.
  • Other Non Operating Income for Q3 2025 was $61000.0 at Aptevo Therapeutics, up from $22000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $37.2 million in Q2 2022 and bottomed at -$41.2 million in Q4 2022.
  • The 5-year median for Other Non Operating Income is $61000.0 (2025), against an average of -$690473.7.
  • The largest annual shift saw Other Non Operating Income plummeted 58650.0% in 2021 before it skyrocketed 1687.62% in 2022.
  • A 5-year view of Other Non Operating Income shows it stood at -$2.6 million in 2021, then crashed by 1511.62% to -$41.2 million in 2022, then skyrocketed by 100.46% to $188000.0 in 2023, then tumbled by 62.77% to $70000.0 in 2024, then fell by 12.86% to $61000.0 in 2025.
  • Per Business Quant, the three most recent readings for APVO's Other Non Operating Income are $61000.0 (Q3 2025), $22000.0 (Q2 2025), and $72000.0 (Q1 2025).